Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Combined with Camrelizumab and Apatinib for Unresectable HCC
NCT06739317Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2025
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Overall Survival at 3 years and The R0 Resection rate of the experimental group at 30 days. Planned start Jan 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06739317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739317.